<DOC>
	<DOCNO>NCT00333827</DOCNO>
	<brief_summary>The purpose study determine effect cell therapy patient severe dilate cardiomyopathy</brief_summary>
	<brief_title>Cell Therapy In Dilated Cardiomyopathy</brief_title>
	<detailed_description>This protocol describe double-blind placebo control randomized clinical trial evaluate efficacy bone marrow derive stem cell implant 300 bazillion patient dilate cardiomyopathy heart failure class III IV New York Heart Association . The primary endpoint study evaluate effect autologous bone marrow stem cell implant increase ejection fraction leave ventricle comparison control group , optimize therapy dilate cardiomyopathy . Secondary endpoint evaluate alteration NYHA functional class , mortality rate , physical capacity ( ergoespirometry ) , life quality ( Minnesota questionnaire ) pulmonary congestion dilate cardiomyopathy patient receive autologous bone-marrow stem cell implant . Hypothesis : The main hypothesis study patient receive autologous bone-marrow stem cell implant 6 month follow-up mean 5 % increase absolute leave ventricle ejection fraction comparison control group .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Diagnosis dilate cardiomyopathy accord WHO criteria Syndromic heart failure functional class III IV NYHA Enrollment continuous followup cardiac outpatient clinic Adequate medical therapy optimization therapy Echocardiogram ejection fraction equal le 35 % Simpson 's rule Valvular disease , except functional mitral tricuspid reflow Coronariography show significant lesion ( obstruction least 50 % lumen troncus main artery LAD , CX , RC ) one arteries Serologic diagnosis Chagas disease least two follow criterion : epidemiology , right bundle branch block , anterior hemiblock , apical aneurism Sustained ventricular tachycardia Abusive use alcohol illicit drug Pregnancy Use cardio toxic drug Any comorbidity impact life expectancy 2 year Renal function compromise ( creatinine 2 mg/dl )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dilated Cardiomyopathy</keyword>
	<keyword>stem cell</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Randomized Controlled Trials</keyword>
</DOC>